研究单位：[1]Daiichi Sankyo, Inc.[2]The Third Xiangya Hospital of Central South University,Changsha,China,410013[3]The Sixth People's Hospital of Chengdu,Chengdu,China,610000[4]West China Hospital Sichuan University,Chengdu,China,610041[5]The First Affiliated Hospital of Dalian Medical University,Dalian,China,116011[6]Fuyang People's Hospital,Fuyang,China,236000[7]Nanfang Hospital Southern Medical University,Guangzhou,China,510510[8]Qilu Hospital of Shandong University,Jinan,China,250012[9]Gaozhou People's Hospital,Maoming,China,525200[10]Peking University Shougang Hospital,Peking,China,100144[11]Huadong Hospital Affiliated To Fudan University,Shanghai,China,200433[12]Shenzhen People's Hospital,Shenzhen,China,518140[13]Tianjin Medical University General Hospital,Tianjin,China,300070[14]The Sixth Hospital of Wuhan,Wuhan,China,430000[15]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China,430030[16]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,China,221004[17]The First Affiliated Hospital of Hebei North University,Zhangjiakou,China,075001[18]Affiliated Hospital of Guangdong Medical University,Zhanjiang,China,523710[19]Henan Provincial People's Hospital,Zhengzhou,China,450003
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation. Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections. This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.
